Abstract |
Lomefloxacin, a new difluorinated quinolone, and trimethoprim/sulfamethoxazole ( TMP/SMX) were compared in the treatment of adults with uncomplicated urinary tract infections. The study was conducted as a multicenter, controlled, prospectively randomized, single-blind study in five countries (Argentina, Belgium, Brazil, Mexico, and Venezuela). A total of 254 patients were enrolled: 129 in the lomefloxacin group and 125 in the TMP/SMX group. Patients received either 400 mg lomefloxacin orally once daily or 160 mg/800 mg TMP/SMX orally twice daily for 7-10 days. Escherichia coli and Proteus mirabilis were the pathogens most frequently isolated. At 5-9 days post- therapy, satisfactory bacteriologic results were noted in 98.4% of patients treated with lomefloxacin and in 95.8% of patients in the TMP/SMX group (p = 0.2153). Clinical success 5-9 days post- therapy was noted in 99.2% of patients in the lomefloxacin group and in 98.3% of patients in the TMP/SMX group (p = 0.5138). Adverse events probably related to treatment occurred in 6% of those treated with lomefloxacin and in 7% of patients treated with TMP/SMX. Once-daily oral lomefloxacin is a well-tolerated and effective treatment of uncomplicated urinary tract infections caused by susceptible pathogens.
|
Authors | J Andrade-Villanueva, A Flores-Gaxiola, P Lopez-Guillen, G Aguirre-Avalos, R Morfin-Otero, E Rodriguez-Noriega |
Journal | The American journal of medicine
(Am J Med)
Vol. 92
Issue 4A
Pg. 71S-74S
(Apr 06 1992)
ISSN: 0002-9343 [Print] United States |
PMID | 1316074
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Quinolones
- Trimethoprim, Sulfamethoxazole Drug Combination
- lomefloxacin
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Infective Agents
(adverse effects, therapeutic use)
- Female
- Fluoroquinolones
- Humans
- Male
- Middle Aged
- Prospective Studies
- Quinolones
(adverse effects, therapeutic use)
- Single-Blind Method
- Trimethoprim, Sulfamethoxazole Drug Combination
(therapeutic use)
- Urinary Tract Infections
(drug therapy, microbiology)
|